Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.

@article{Fisch2003FluoxetineVP,
  title={Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.},
  author={Michael Jordan Fisch and Patrick J. Loehrer and J. Kristeller and Steven D. Passik and Sin-Ho Jung and Jianzhao Shen and Matthew A. Arquette and Mary Jacqueline Brames and Lawrence Henry Einhorn},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 10},
  pages={1937-43}
}
PURPOSE To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey. PATIENTS AND METHODS One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine (20 mg daily) or placebo for 12 weeks. Patients were screened for at least minimal depressive symptoms and assessed every 3… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

The treatment of depression in cancer patients: a systematic review

Supportive Care in Cancer • 2006
View 17 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…